Current Report Filing (8-k)
March 20 2017 - 9:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported)
|
March 14, 2017
|
Accelerate
Diagnostics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-31822
|
84-1072256
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
3950 South Country Club, Suite 470, Tucson, Arizona
|
85714
|
(Address of principal executive offices)
|
(Zip Code)
|
(520)
365-3100
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
On March 14, 2017, the Board of Directors
(the “Board”) of Accelerate Diagnostics, Inc. (the “Company”) increased the size of the Board to seven
(7) members and elected Tom Brown as a director of the Company, effective immediately. The Board has not yet appointed Mr. Brown
to any committees, though it may appoint him to one or more committees in the future. On March 15, 2017, the Company issued a press
release announcing Mr. Brown’s appointment to the board, a copy of which is attached hereto as Exhibit 99.1 and is incorporated
by reference.
Mr. Brown will receive the standard compensation
for non-employee directors as described in the Company’s most recent proxy statement on Schedule 14A dated April 1, 2016.
Except as described above, Mr. Brown was
not selected as a director of the Company pursuant to any arrangement or understanding between him and any other person.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits. The
following material is filed as an exhibit to this Current Report on Form 8-K:
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated March 15, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ACCELERATE DIAGNOSTICS, INC.
(Registrant)
|
|
|
|
|
Date: March 20, 2017
|
/s/ Steve Reichling
|
|
Steve Reichling
Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated March 15, 2017
|
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Sep 2023 to Sep 2024